Are Nice And The SMC Diverging In Their Assessment Of Oncology Drugs?

October 4, 2018 Danielle Twigg

The National Institute of Health and Care Excellence (NICE) and Scottish Medicines Consortium (SMC) make recommendations on whether health technologies should be publically-reimbursed in England/Wales and Scotland, respectively, based on their clinical- and cost-effectiveness. Recently, both SMC and NICE have implemented divergent reforms to their appraisal processes including the NICE reformation of the Cancer Drugs Fund and the SMC Patient and Clinician Engagement (PACE) process. This research compares outcomes of NICE and SMC appraisals of oncology drugs over time.

Authors: Macaulay R, Berardi A, Wang GD, Kasli I

To find out more about this poster you can register to download it here after the ISPOR event.

 

Previous Article
A Budget Impact Analysis Of Cladribine Tablets Versus Alternative High Efficacy Treatments For Relapsing Multiple Sclerosis (RMS) In The UK
A Budget Impact Analysis Of Cladribine Tablets Versus Alternative High Efficacy Treatments For Relapsing Multiple Sclerosis (RMS) In The UK

Next Article
Pan-European HTA – Where We Have Been, Where We Are Going?
Pan-European HTA – Where We Have Been, Where We Are Going?